Recombinant Mouse SP-D Protein(His Tag)

Catalog Number: PDMM100105

Note: Centrifuge before opening to ensure complete recovery of vial contents.

Description			
Species	Mouse		
Source	Mammalian-derived Mouse SP-D proteins Ala20-Phe374, with an C-terminal His		
Calculated MW	38.9 kDa		
Observed MW	40-50 kDa		
Accession	P50404		
Bio-activity	Not validated for activity		
Properties			
Purity	> 90% as determined by reducing SDS-PAGE.		
Endotoxin	< 1.0 EU/mg of the protein as determined by the LAL method		
Storage	Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80		
	°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of		
	reconstituted samples are stable at $< -20^{\circ}$ C for 3 months.		
Shipping	This product is provided as lyophilized powder which is shipped with ice packs.		
Formulation	Lyophilized from a 0.2 μ m filtered solution in PBS with 5% Trehalose and 5%		
	Mannitol.		
Reconstitution	It is recommended that sterile water be added to the vial to prepare a stock solution of		
	0.5 mg/mL. Concentration is measured by UV-Vis.		

Data

kDa 80 60	M	R	
40	_	W	
30	-		
20	-		
12			

SDS-PAGE analysis of Mouse SP-D proteins, 2 µg/lane of Recombinant Mouse SP-D proteins was resolved with an SDS-PAGE under reducing conditions, showing bands at 38.9KD

Background

For Research Use Only

Elabscience®

Surfactant pulmonary-associated protein D, also known as SFTPD and SP-D, is a member of the collectin family of Ctype lectins that is synthesized in many tissues including respiratory epithelial cells in the lung, and contains one C-type lectin domain and one collagen-like domain. The polymorphic variation in the N-terminal domain of the SP-D molecule influences oligomerization, function, and the concentration of the molecule in serum. SFTPD is produced primarily by alveolar type II cells and nonciliated bronchiolar cells in the lung and is constitutively secreted into the alveoli where it influences surfactant homeostasis, effector cell functions, and host defense. It is upregulated in a variety of inflammatory and infectious conditions including Pneumocystis pneumonia and asthma. SFTPD is humoral molecules of the innate immune system, and is considered a functional candidate in chronic periodontitis. Besides, it is involved in the development of acute and chronic inflammation of the lung. Several Human lung diseases are characterized by decreased levels of bronchoalveolar SFTPD. Thus, recombinant SFTPD has been proposed as a therapeutical option for cystic fibrosis, neonatal lung disease and smoking-induced emphysema. Furthermore, SFTPD serum levels can be used as disease activity markers for interstitial lung diseases.